Pancreas Transplant Pathology: Controversial Lesions Lois J. Arend PhD, MD University of Cincinnati Department of Pathology.

Slides:



Advertisements
Similar presentations
Dr. Gehan Mohamed Dr. Abdelaty Shawky
Advertisements

Transplant Immunology & Renal Allograft Rejection
Significance of the total i-score
Case no. 7. Eva Honsova Institute for Clinical and Experimental Medicine Pathology Department Prague, Czech Republic
Chronic vascular injury of the kidney allograft: The contribution of rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University.
Complement in Heart Allograft Biopsies E. Rene Rodriguez W. M. Baldwin, III.
Michael Mengel Department of Laboratory Medicine and Pathology
Kidney allografts with biopsy features of chronic mixed rejection reflect poorer survival than those with pure chronic antibody-mediated rejection D. Dobi,
Al-Qassim University Faculty of Medicine Phase II – Year III GIT Block (CMD332) EXOCRINE PANCREASE Lecture Dr. Gamal Hamra Wednesday 01/12/1430 (18/11/2009)
The Value of Zero-Hour Implantation Biopsies Volker Nickeleit Nephropathology Laboratory, Department of Pathology The University of North Carolina, Chapel.
PATHOLOGIC DIAGNOSIS OF ANTIBODY-MEDIATED REJECTION (AMR) Histopathologic findings Immunopathologic findings Immunohistochemistry on paraffin sections.
Banff 2001 Liver Group Discussions. 1. Rejection 2.Centrilobular (zone 3) inflammatory lesions 3.Changes in late post-transplant biopsies Banff
Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature.
POLYOMAVIRUS INFECTION IN RENAL ALLOGRAFTS: PROGRESS SINCE BANFF 1999 Parmjeet Randhawa Associate Professor Division of Transplantation Pathology Department.
The value of protocol biopsies in renal allografts Gordana Petrusevska Skopje, Macedonia Gordana Petrusevska Skopje, Macedonia.
BANFF SCHEMA FOR GRADING PANCREAS ALLOGRAFT REJECTION
Slide 1PUBLICATIONS Racusen/Solez meeting report for AJT. Racusen/Solez meeting report for AJT. Manuscript on antibody-mediated rejection. Manuscript on.
Pancreas Transplant Pathology: A Surgeon’s Perspective Jon Odorico M.D., F.A.C.S. University of Wisconsin-Madison.
Jeremy Chapman Westmead Hospital, Sydney CMV Infection and Allograft Rejection : Are we missing the point?
Sum Scores & Components’ Scores Chronic Scores Acute Rejection Scores Lillian W. Gaber University of Tennessee.
Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.
Journal Reading Present by Dr. 陳志榮. The Banff 97 Working Classification of Renal Allograft Pathology Racusen LC, Solez K, Colvin RB, Bonsib.
Banff 2003 Liver Session Summary. Distribution of Banff Severity of Acute Rejection Graft Failure from Acute or Chronic Rejection 575/901 patients 64%
The Banff Classification: Slide Seminar Kim Solez, M.D.
GRADING OF REJECTION IN PANCREAS ALLOGRAFTS Are changes needed? Cinthia B. Drachenberg, M.D. University of Maryland School of Medicine Baltimore MD.
Summaries by Session Chairs of Banff 2003: C4d scoring/Ab mediated reject. - Bob Colvin GeneAnalysis/Microarrays/Tubulitis/Tolerance - Lorraine Racusen.
HISTOPATHOLOGY OF PANCREAS TRANSPLANTATION
Slide Seminar Drugs and Kidney Case 3 Heinz Regele Department of Pathology.
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
BACKGROUND ON PANCREAS HISTOLOGICAL FINDINGS: University of Maryland experience John C. Papadimitriou, M.D.,Ph.D. Professor of Pathology.
Lesley Stevens MD Tufts-New England Medical Center
Chapter 19 The Pancreas.
Examining the carcinogenic potential of pancreatic inflammation in obese mice with maspin staining Janessa Pennington 1, Mariah Gawlik 1, Betty Herndon.
Monitoring HLA-specific antibodies
Diseases of the Pancreas November 19, 2007 NCDD Meeting Chair: Jane Holt Vice Chair: P. Jay Pasricha, MD.
Pathology of Kidney and the Urinary tract
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
Severe vascular lesions and poor functional outcome
Interactive Case Discussion Case 6 Dr Megha S Uppin Asst Prof Dept of Pathology Nizam’s Institute of Medical Sciences Hyderabad.
Kidney transplant case Niels Marcussen Hans Dieperink Odense University Hospital.
Humoral rejection: What the pathologist needs to know Humoral rejection: What the pathologist needs to know Heinz Regele Heinz Regele Clinical Institute.
Pathology of Kidney and the Urinary tract Dr. Amar C. Al-Rikabi Dr. Hala Kasouf Kfouri.
Prognostic significance of C4-positive vs. negative rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University Heinz Regele.
Fabry disease in donor kidneys with 3 and 12 years follow-up after transplantation Willy Aasebø 1, Erik H. Strøm 2, Torstein Hovig 2, Liv H. Undset 1 Arvid.
UK National Renal Transplant EQA Scheme Ian Roberts Department of Cellular Pathology, Oxford Radcliffe Hospitals The National Renal Transplant EQA Scheme.
C4d in pancreas transplant biopsies: the Leiden experience Ingeborg Bajema Ingeborg Bajema Ingeborg Bajema.
Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.
Autoimmune Diseases How Do the Immune Cells of the Body Know What to Attack and What Not To Attack ?
Reference: Gloor J, Stegall MD
Pathology of Renal Transplantation
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Acute rejection after kidney transplantation
The significance of Focal C4d+: The WU experience Helen Liapis, M.D. Professor of Pathology & immunology Kedainis RL et al. Am J Transplant Apr;9(4):812-9.
Smooth muscle–specific actin levels in the urine of renal transplant recipients: Correlation with cyclosporine or tacrolimus nephrotoxicity  Mark Haas,
Mechanism and Treatment of Antibody-Mediated Rejection
T. N. Nikonenko, A. V. Trailin and A. S. Nikonenko
Liver Transplantation: 50 years
Chapter 12 Liver Transplantation 1
a b c d e Supplemental figure 4
Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.
Acute Rejection, Types II & III (Vascular)
Transplantation Immunology
Volume 67, Issue 1, Pages (January 2005)
An Observational Study on Thrombotic Microangiopathy in Renal Transplant Recipients - A Tertiary Care Centre Experience. Dr Sarang Vijayan Senior Resident.
Acute Humoral Rejection
Chapter 5: Renal Allograft Biopsy Wong Hin Seng
Transplantation Immunology
Proteasome inhibitor-based therapy for antibody-mediated rejection
Post-transplant membranous glomerulonephritis as a manifestation of chronic antibody-mediated rejection Hyeon Joo Jeong, Beom Jin Lim, Myoung Soo Kima,
Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.
Presentation transcript:

Pancreas Transplant Pathology: Controversial Lesions Lois J. Arend PhD, MD University of Cincinnati Department of Pathology

American Journal of Transplantation 2008; 8: 1237–1249 Banff Schema for Grading Pancreas Allograft Rejection: Working Proposal by a Multi-Disciplinary International Consensus Panel C. B. Drachenberg, J. Odorico, A.J. Demetris, L. Arend, I. M. Bajema, J. A. Bruijn, D. Cantarovich, H. P. Cathro, J. Chapman, K. Dimosthenous, B. Fyfe-Kirschner, L. Gaber, O. Gaber, J. Goldberg, E. Honsova, S. S. Iskandar, D. K. Klassen, B. Nankivell, J. C. Papadimitriou, L. C. Racusen, P. Randhawa, F. P. Reinholt, K. Renaudin, P. P. Revelo, P. Ruiz, J. R. Torrealba, E. Vazquez-Martul, L. Voska, R. Stratta, S. T. Bartlett and D. E. R. Sutherland

1. Normal 2. Indeterminate 3. Cell-mediated rejection Acute cell-mediated rejection - Grade I/Mild acute cell-mediated rejection - Grade II/Moderate acute cell-mediated rejection - Grade III/Severe acute cell-mediated rejection Chronic active cell-mediated rejection 4. Antibody-mediated rejection = C4d + donor specific antibodies + graft dysfunction Hyperacute rejection Accelerated antibody-mediated rejection Acute antibody-mediated rejection Chronic active antibody-mediated rejection 5. Chronic allograft rejection/graft sclerosis - Stage I (mild graft sclerosis) - Stage II (moderate graft sclerosis) - Stage III (severe graft sclerosis) 6. Other histological diagnosis. e.g. CMV pancreatitis, PTLD, etc. Allograft Pancreas Grading American Journal of Transplantation 2008; 8: 1237–1249

Outline Drug Toxicity Significance of C4d Labeling Significance of Acinar Inflammation Chronic Rejection/Sclerosis

Drug Toxicity Exocrine pancreas –Acute pancreatitis Anti-neoplastics, sulfonamides, diuretics, alcohol, azathioprine, oral contraceptives Acinar cell necrosis or apoptosis, inflammation, necrosis Endocrine pancreas – Diabetes Calcineurin inhibitors, thiazide diuretics Vacuolation, swelling, apoptosis of islet cells Reduced insulin staining of beta cells

Exocrine Pancreas Acute pancreatitis –Drugs, duct obstruction, viruses, toxic chemicals, trauma Some features of acute pancreatitis can overlap with acute rejection Distinguishing between the two can be difficult Venulitis and more mononuclear dominant infiltrate favors rejection Many centers will treat for rejection if no clinical reason for pancreatitis is evident

Endocrine Pancreas Diabetes –Caused by immunosuppressive agents No inflammation – vacuolation or drop-out –Caused by recurrent autoimmune disease Mononuclear cell infiltrate, similar to rejection –Should routine immunostaining be included as part of the grading scheme? Immunostaining for insulin and glucagon may not be routine at some centers

Significance of C4d Staining Antibody-mediated rejection, complement activation, deposition on endothelial cells –Indication of AMR Acute Chronic? Accessibility of staining by IHC on paraffin Non-specificity of paraffin section staining Frozen sections for IF?

Significance of C4d Staining Correlation between C4d+ IAC and: –Development of DSA –Allograft dysfunction C4d staining of artery intima or media, and interstitial collagen –No correlation with DSA or dysfunction Islet capillaries –No correlation with DSA or blood glucose C4d+ IAC correlated with DSA and graft dysfunction Torrealba, et al Transplantation 2008; 86: 1849

Retrospective Review of C4d Staining 2003 – biopsies with C4d immunostaining performed 2 cases with C4d+ IAC labeling No correlation with rejection grade –Sclerosing grade III; ACR III (old grade V) DSA not available

Significance of Acinar Inflammation – Mild acinar inflammation and injury to acinar cells (Grade I) Acinar injury easily leads to fibrosis Fibrosis -> poor prognosis

Significance of Acinar Inflammation – Mayo clinic study 2 year period – 18 biopsies for grade II 25 follow-up biopsies 10 were unchanged, 1 grade III, 1 grade IV Conclusion: Grade II may not have unfavorable prognosis Casey, et al., Transpl, 2005

Significance of Acinar Inflammation – Minnesota study 8 year period – 914 pancreas grafts 80 grafts lost to chronic rejection 91% of these had prior rejection episode 70% with late functioning grafts had never had acute rejection Humar, et al., Transpl, 2003

Cincinnati Experience – Small sample Two cases with Grade II rejection One graft progressed to Stage III sclerosis in one year One graft progressed to Stage III sclerosis in nine months

1 month post-txp

4 months post-txp

7 months post-txp

10 months post-txp

12 months post-txp

Proposal – Should acinar inflammation of any degree be considered severe and treated aggressively? –Septal category of rejection –Acinar category –Arteritis category

Treatment of rejection Treat any form of pancreatic rejection aggressively –All but mildest cases treated with anti- thymocyte therapy Low threshold for treatment of pancreas rejection

Chronic Rejection/Sclerosis Is graft sclerosis always due to rejection? Drug toxicity, infections, vascular complications Avoid CAN analog ?CAP Distinguish cause of sclerosis if possible

Summary Distinguishing rejection from many other insults can be difficult Significance of C4d+ unclear Any degree of acinar inflammation may benefit from early aggressive treatment Defining causes of chronic injury Rejection grade correlation with outcome

Acknowledgements Surgery Steve Woodle, MD Transplant Pharmacy Jason Everly, PharmD Rita Alloway, PharmD Nephrology Prabir Roy-Chaudhury, MD Gautham Mogilishetty, MD Amit Govil, MD Pathology Pravina Desai NEJM 356; 2007